These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28444425)

  • 1. Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis.
    Indhumathi S; Rajappa M; Chandrashekar L; Ananthanarayanan PH; Thappa DM; Negi VS
    Eur J Clin Pharmacol; 2017 Aug; 73(8):965-971. PubMed ID: 28444425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T helper-2 cytokine/regulatory T-cell gene polymorphisms and their relation with risk of psoriasis in a South Indian Tamil cohort.
    Indhumathi S; Rajappa M; Chandrashekar L; Ananthanarayanan PH; Thappa DM; Negi VS
    Hum Immunol; 2017 Feb; 78(2):209-215. PubMed ID: 28027921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment.
    West J; Ogston S; Berg J; Palmer C; Fleming C; Kumar V; Foerster J
    Clin Exp Dermatol; 2017 Aug; 42(6):651-655. PubMed ID: 28512993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of association of the IL-12B and IL-23R genetic variations with psoriatic risk in a South Indian Tamil cohort.
    Indhumathi S; Rajappa M; Chandrashekar L; Ananthanarayanan PH; Thappa DM; Negi VS
    Hum Immunol; 2016 Jan; 77(1):54-62. PubMed ID: 26472011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
    Talamonti M; Botti E; Galluzzo M; Teoli M; Spallone G; Bavetta M; Chimenti S; Costanzo A
    Br J Dermatol; 2013 Aug; 169(2):458-63. PubMed ID: 23521149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Risk of Psoriasis due to combined effect of HLA-Cw6 and LCE3 risk alleles in Indian population.
    Chandra A; Lahiri A; Senapati S; Basu B; Ghosh S; Mukhopadhyay I; Behra A; Sarkar S; Chatterjee G; Chatterjee R
    Sci Rep; 2016 Apr; 6():24059. PubMed ID: 27048876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.
    Ryan C; Kelleher J; Fagan MF; Rogers S; Collins P; Barker JN; Allen M; Hagan R; Renfro L; Kirby B
    Clin Exp Dermatol; 2014 Jun; 39(4):519-24. PubMed ID: 24758522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab.
    De Keyser E; Busard CI; Lanssens S; Meuleman L; Hutten BA; Costanzo A; van den Reek JM; Zweegers J; Lambert J; Spuls PI
    Ther Drug Monit; 2019 Oct; 41(5):634-639. PubMed ID: 31107404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients.
    Batalla A; Coto E; González-Fernández D; González-Lara L; Gómez J; Santos-Juanes J; Queiro R; Coto-Segura P
    Pharmacogenet Genomics; 2015 Jun; 25(6):313-6. PubMed ID: 25794162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
    Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
    Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HLA-C*06 allele as a possible genetic predisposing factor to psoriasis in South Indian Tamils.
    Indhumathi S; Rajappa M; Chandrashekar L; Ananthanarayanan PH; Thappa DM; Negi VS
    Arch Dermatol Res; 2016 Apr; 308(3):193-9. PubMed ID: 26796545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.
    Costanzo A; Bianchi L; Flori ML; Malara G; Stingeni L; Bartezaghi M; Carraro L; Castellino G;
    Br J Dermatol; 2018 Nov; 179(5):1072-1080. PubMed ID: 29704432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6.
    Riveira-Munoz E; He SM; Escaramís G; Stuart PE; Hüffmeier U; Lee C; Kirby B; Oka A; Giardina E; Liao W; Bergboer J; Kainu K; de Cid R; Munkhbat B; Zeeuwen PL; Armour JA; Poon A; Mabuchi T; Ozawa A; Zawirska A; Burden AD; Barker JN; Capon F; Traupe H; Sun LD; Cui Y; Yin XY; Chen G; Lim HW; Nair RP; Voorhees JJ; Tejasvi T; Pujol R; Munkhtuvshin N; Fischer J; Kere J; Schalkwijk J; Bowcock A; Kwok PY; Novelli G; Inoko H; Ryan AW; Trembath RC; Reis A; Zhang XJ; Elder JT; Estivill X
    J Invest Dermatol; 2011 May; 131(5):1105-9. PubMed ID: 21107349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPR1 gene near HLA-C is unlikely to be a psoriasis susceptibility gene.
    Chang YT; Tsai SF; Lin MW; Liu HN; Lee DD; Shiao YM; Chin PJ; Wang WJ
    Exp Dermatol; 2003 Jun; 12(3):307-14. PubMed ID: 12823445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Mapping of Genetic Interactions between HLA-Cw6 and LCE3A in Psoriasis.
    Chandra A; Das S; Mazumder S; Senapati S; Chatterjee G; Chatterjee R
    J Invest Dermatol; 2021 Nov; 141(11):2630-2638.e7. PubMed ID: 34029573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics and the resulting impact on psoriasis therapies.
    Foulkes AC; Warren RB
    Dermatol Clin; 2015 Jan; 33(1):149-60. PubMed ID: 25412789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.
    Berna-Rico E; Perez-Bootello J; Abbad-Jaime de Aragon C; Gonzalez-Cantero A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37372997
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Morelli M; Galluzzo M; Madonna S; Scarponi C; Scaglione GL; Galluccio T; Andreani M; Pallotta S; Girolomoni G; Bianchi L; Talamonti M; Albanesi C
    Expert Opin Biol Ther; 2021 Feb; 21(2):259-270. PubMed ID: 33297781
    [No Abstract]   [Full Text] [Related]  

  • 19. A preliminary prospective non-randomized controlled trial to compare the efficacy of subcutaneous etanercept versus oral methotrexate in moderate-to-severe chronic plaque psoriasis and correlation of response with T helper (th) 1, th2, th17 and T regulatory cytokine patterns.
    Khandpur S; Singh A; Kumar A; Sharma A
    Indian J Dermatol Venereol Leprol; 2020; 86(4):441-445. PubMed ID: 32496226
    [No Abstract]   [Full Text] [Related]  

  • 20. TT genotype of rs10036748 in TNIP1 shows better response to methotrexate in a Chinese population: a prospective cohort study.
    Yan KX; Zhang YJ; Han L; Huang Q; Zhang ZH; Fang X; Zheng ZZ; Yawalkar N; Chang YL; Zhang Q; Jin L; Qian DF; Li XY; Wu MS; Xu QH; Zhang XJ; Xu JH
    Br J Dermatol; 2019 Oct; 181(4):778-785. PubMed ID: 31020648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.